Call for papers
The Ukrainian Biochemical Journal launches a call for papers for a special issue on Clinical and Molecular Studies of Hemostasis. It is scheduled for publication on July 2020 (Vol. 92, No 3).
Submission deadline: 15 February, 2020.
The Journal welcomes original research, review articles, short reports concerning the principles of regulation of the blood coagulation system, its interaction with blood cells or immune system, recent findings on fibrinogen structure and fibrin polymerization mechanisms. Medical aspects of hemostasis and pathogenesis of hemostasis-related disorders are also welcome.
By publication of this Issue we aim to praise the outstanding progress in hemostasis studies all over the globe and also to revitalize the knowledge about the role of the scientific school founded by Ukrainian biochemist academician Volodymyr Belitser (1906-1988) which was a home for many scientists and current members of IFRS.
Ukrainian Biochemical Journal is the main Ukrainian biochemical-biomedical resource that is listed in Scopus, WoS, CrossRef, Medline, DOAJ, Embase, CAS, and Google Scholar. Its online version is posted on the EBSCO and Elsevier portals. All articles are available as open access articles.
All submitted papers will undergo the standard independent peer-review process.
Manuscripts should be submitted via online submission service (For Authors: http://ukrbiochemjournal.org/rules-for-authors).
Upon submission, the following documents must be uploaded along with your manuscript: (i) a License Agreement on copyright transfer to the publisher – a scanned copy, and (ii) a Conflict of Interest Disclosure Form.
The License Agreement before scanning should be duly signed by all authors.
Do not hesitate to contact the coordinators of the project: executive editor of the Journal Dr Maya Grigorieva (email@example.com) and Dr Volodymyr Chernyshenko (firstname.lastname@example.org).
Cover of journal: http://ukrbiochemjournal.org/wp-content/uploads/2015/03/cover_biochem_no1_2015-215x300.jpg
graph text here.